GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Sep 2022 07:00 AM
RNS
GSK Chief Financial Officer succession
22 Sep 2022 02:00 PM
RNS
US FDA ODAC review of Zejula Phase III NOVA trial
22 Sep 2022 07:00 AM
RNS
GSK and Spero Therapeutics licence for tebipenem
21 Sep 2022 11:22 AM
RNS
Director/PDMR Shareholding
13 Sep 2022 09:11 AM
RNS
Director/PDMR Shareholding
08 Sep 2022 12:58 PM
RNS
Director/PDMR Shareholding
06 Sep 2022 01:00 PM
RNS
GSK provides update on FDA review of daprodustat
01 Sep 2022 11:48 AM
RNS
Total Voting Rights
24 Aug 2022 07:00 AM
RNS
GSK Board changes
22 Aug 2022 04:53 PM
RNS
Director/PDMR Shareholding
17 Aug 2022 07:00 AM
RNS
FDA New Drug Application File Acceptance for MMB
17 Aug 2022 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation update
16 Aug 2022 07:06 AM
RNS
GSK completes acquisition of Affinivax, Inc.
12 Aug 2022 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
11 Aug 2022 11:51 AM
RNS
Director/PDMR Shareholding
10 Aug 2022 04:57 PM
RNS
Director/PDMR Shareholding
01 Aug 2022 06:10 PM
RNS
Total Voting Rights
01 Aug 2022 01:43 PM
RNS
Director/PDMR Shareholding
29 Jul 2022 02:00 PM
RNS
Director/PDMR Shareholding
29 Jul 2022 10:00 AM
RNS
GSK Board change
28 Jul 2022 01:01 PM
RNS
Director/PDMR Shareholding
27 Jul 2022 07:00 AM
RNS
2nd Quarter Results
22 Jul 2022 04:45 PM
RNS
Holding(s) in Company
22 Jul 2022 04:17 PM
RNS
Board and Committee Changes
19 Jul 2022 07:00 AM
RNS
Completion of GSK Share Consolidation
18 Jul 2022 07:00 AM
RNS
Haleon demerger completion and share consolidation
12 Jul 2022 09:48 AM
RNS
Director/PDMR Shareholding
08 Jul 2022 06:04 PM
RNS
Director/PDMR Shareholding
08 Jul 2022 05:30 PM
RNS
Director/PDMR Shareholding
08 Jul 2022 03:53 PM
RNS
Director/PDMR Shareholding
08 Jul 2022 03:33 PM
RNS
Director/PDMR Shareholding
08 Jul 2022 03:10 PM
RNS
Director/PDMR Shareholding
06 Jul 2022 04:30 PM
RNS
Result of General Meeting
06 Jul 2022 10:11 AM
RNS
Director/PDMR Shareholding
05 Jul 2022 12:43 PM
RNS
GSK disclose discontinued operations from Q2 2022
05 Jul 2022 09:45 AM
RNS
Director/PDMR Shareholding
05 Jul 2022 09:30 AM
RNS
Director/PDMR Shareholding
01 Jul 2022 03:27 PM
RNS
Total Voting Rights
01 Jul 2022 02:45 PM
RNS
GSK completes acquisition of Sierra Oncology
28 Jun 2022 05:56 PM
RNS
Director/PDMR Shareholding
28 Jun 2022 07:00 AM
RNS
GSK files Shingrix 18+ at risk indication in Japan
27 Jun 2022 04:08 PM
RNS
Director/PDMR Shareholding
24 Jun 2022 03:44 PM
RNS
Director/PDMR Shareholding
16 Jun 2022 10:58 AM
RNS
Director/PDMR Shareholding
10 Jun 2022 07:00 AM
RNS
Positive phase III data for GSK's RSV OA vaccine
09 Jun 2022 04:28 PM
RNS
Director/PDMR Shareholding
07 Jun 2022 05:17 PM
RNS
Director/PDMR Shareholding
07 Jun 2022 12:00 PM
EQS
Hardman & Co Life Sciences Research: Long-t...
06 Jun 2022 07:00 AM
RNS
US FDA approval of Priorix
01 Jun 2022 04:55 PM
RNS
Total Voting Rights

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings